Clinical Edge Journal Scan

Gastric cancer: Neoadjuvant treatment status should not guide the extent of lymphadenectomy


 

Key clinical point: Routine D2-lymphadenectomy should be performed during total and distal gastrectomy in patients with gastric cancer even after administering neoadjuvant chemotherapy (NAC).

Major finding: cT2, cT3, and cT4 stage tumors metastasized to all individual lymph node (LN) stations (1-9, 11, and 12a). Patients who did vs did not receive NAC had a numerically lower incidence of metastases in almost all stations (54% vs 63%) but a similar distribution of LN metastases over the different stations.

Study details: This side-study of the LOGICA trial included 212 patients with resectable gastric cancer who underwent total or distal D2-gastrectomy with en-bloc D2-lymphadenectomy combined with total omentectomy, of which 158 received NAC and 120 had LN metastases.

Disclosures: The LOGICA trial was sponsored by ZonMw (The Netherlands Organization for Health Research and Development); this side-study received no funding. Some authors declared serving as consultants or advisors for or receiving research funding and travel or accommodation fees and expenses from various sources.

Source: de Jongh C et al and the LOGICA Study Group. Pattern of lymph node metastases in gastric cancer: A side-study of the multicenter LOGICA-trial. Gastric Cancer. 2022 (Sep 14). Doi: 10.1007/s10120-022-01329-2

Recommended Reading

Liver-dominant mCRC: Prognostic factors for efficacy outcomes after TARE
MDedge Hematology and Oncology
Emergency readmission frequent after curative intent CRC surgery
MDedge Hematology and Oncology
Longer interval between bevacizumab exposure and CRC surgery could prevent additional mortality risk
MDedge Hematology and Oncology
FDA approves new immunotherapy combo for liver cancer
MDedge Hematology and Oncology
Pancreatic cancer screening appears safe, effective for high-risk patients
MDedge Hematology and Oncology
EUS-guided RF ablation doubles survival for unresectable pancreatic cancer
MDedge Hematology and Oncology
Some young CRC patients are missing out on genetic counseling, testing
MDedge Hematology and Oncology
Paclitaxel + carboplatin + capecitabine regimen shows promise in advanced gastric cancer
MDedge Hematology and Oncology
Robotic-assisted distal gastrectomy: A feasible treatment option for advanced gastric cancer
MDedge Hematology and Oncology
Multimodal treatment of gastric cancer affects outcomes in a stage‐specific manner
MDedge Hematology and Oncology